Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells

Pemetrexed (PEM) is a useful drug that can be combined with immune checkpoint blockade therapy for treatment of patients with advanced non–small‐cell lung cancer (NSCLC). However, its effects on anti–cancer immunity, especially the sensitivity of NSCLC cells to cytotoxic immune cells, have not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Okimoto, Tamio, Kotani, Hitoshi, Iida, Yuichi, Koyanagi, Akira, Tanino, Ryosuke, Tsubata, Yukari, Isobe, Takeshi, Harada, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293070/
https://www.ncbi.nlm.nih.gov/pubmed/32232903
http://dx.doi.org/10.1111/cas.14401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293070/
https://www.ncbi.nlm.nih.gov/pubmed/32232903
http://dx.doi.org/10.1111/cas.14401

Ejemplares similares